3 -Methylphthalanilic Acid Berberis Vulgaris Root

證據等級: L5

預測適應症: 0 個

Multi-Component Mixture (6 Substances): Evaluation Report — Insufficient Data for Repurposing Assessment

One-Sentence Summary

This Evidence Pack describes a complex mixture of six substances — including botanical extracts (Berberis vulgaris root bark, Chelidonium majus), an animal-derived ingredient (Bos taurus bile), and synthetic compounds (3’-Methylphthalanilic acid, Propham, Proxifezone) — with no original approved indication on record. The TxGNN model returned no predicted indications for this combination, and the substance has no regulatory approval in the United States, leaving this candidate without a viable repurposing direction at this time. The overall evidence base is essentially absent, and the candidate cannot proceed past initial triage without substantial data remediation.

Quick Overview

Item	Content
Original Indication	None on record
Predicted New Indication	None (TxGNN returned no candidates)
TxGNN Prediction Score	N/A
Evidence Level	L5 — Model prediction only (no predictions returned)
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No repurposing prediction is available for this candidate. The TxGNN model returned an empty predicted_indications list, which typically occurs when the query substance cannot be resolved to a DrugBank node in the knowledge graph (no drugbank_id was assigned), preventing the model from computing any drug–disease association scores.

The query string itself is a semicolon-delimited list of six chemically heterogeneous substances. Three are botanical or animal-derived (Berberis vulgaris root bark, Chelidonium majus whole, Bos taurus bile), one is a documented plant-growth regulator with carbamate structure (Propham), and the identities of 3’-Methylphthalanilic acid and Proxifezone in a clinical context could not be confirmed from available data. TxGNN is designed to operate on single, well-characterised small molecules mapped to DrugBank; multi-component queries of this nature routinely fail to resolve.

Currently, detailed mechanism of action data is not available. Based on known information, the individual components belong to disparate pharmacological classes with no common mechanistic thread, making a unified repurposing rationale impossible to construct without first decomposing the mixture and evaluating each active moiety independently.

Conclusion and Next Steps

Decision: Hold

Rationale: The candidate cannot be evaluated for repurposing because the TxGNN model produced no predictions, the substance has no DrugBank identifier, no approved indication, and all safety data are flagged as data gaps; there is no scientific basis on which to recommend proceeding.

To proceed, the following is needed:

Decompose the mixture: Evaluate each of the six components as separate TxGNN queries after confirming their individual INN/DrugBank identities.
Resolve DrugBank IDs: At minimum for Proxifezone and 3’-Methylphthalanilic acid, which could not be automatically matched; manual lookup in DrugBank or ChEMBL is required.
Clarify Propham’s role: Propham is primarily registered as an agricultural herbicide (ISO 1750); if present in a human-use formulation, its regulatory and toxicological status must be confirmed before any repurposing analysis.
Source original indication data: Identify the original approved context (if any) for this combination from historical TFDA records or the originating manufacturer’s documentation.
Obtain safety data (DG001): Download and parse the package insert PDF from TFDA to populate key warnings and contraindications before any safety screen can be completed.
Obtain MOA data (DG002): Query DrugBank API for each resolved component to enable mechanism-based plausibility assessment.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.